Program
trenibotulinumtoxinE
Also written as “AGN-151586” and “TrenibotulinumtoxinE and OnabotulinumtoxinA”.
Its studies are led by AbbVie.
Furthest: phase 3, since Feb 14, 202211 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 113 open or running | phase 3since Feb 14, 2022 | Sep 4, 2019 | Feb 2027phase 1 · NCT07756580 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 4, 2019First study: phase 2 study in Glabellar LinesFirst studyNCT04096326 · 198 enrolled · United States
- Feb 14, 20223 phase 3 studies in Glabellar LinesNCT05248893, NCT05248880, NCT05248867
- Aug 9, 2022Phase 1 study in Glabellar LinesNCT05496335 · 90 enrolled · United States
- Nov 22, 2023Phase 1 study in Moderate to Severe Glabellar LinesNCT06151561 · 24 enrolled · Japan
- Mar 7, 2024Phase 3 study in Glabellar LinesNCT06308198 · 161 enrolled · China, Japan, Taiwan
- Feb 14, 2025Phase 1 study in Glabellar LinesNCT06834789 · 132 enrolled · United States
- Jul 23, 2026Phase 2 study in Forehead LinesNCT07730554 · 84 enrolled · United States
- Aug 7, 2026Phase 1 study in Glabellar LinesNCT07756580 · 143 enrolled · United States
- Oct 7, 2026Phase 2 study in Upper Facial LinesNCT07871513 · 300 planned · United States
Ahead
- Feb 2027Primary completion: phase 1 study in Glabellar LinesNCT07756580
- Jun 2028Primary completion: phase 2 study in Upper Facial LinesNCT07871513
TargetBeta
SNAP25 →read by rule
“Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme”ChEMBL 37, by rule
Other programs on SNAP25
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| botulinum toxin type A | AbbVie | phase 4 | 286 |
| prabotulinumtoxin Arule | aeon-biopharma-inc | phase 3 | 9 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07871513Upper Facial Lines · United States | 2 | Recruiting | Jun 2028 | 300 |
| NCT07756580Glabellar Lines · United States | 1 | Active, not recruiting | Feb 2027 | 143 |
| NCT07730554Forehead Lines · United States | 2 | Active, not recruiting | Oct 2026 | 84 |
| NCT06834789Glabellar Lines · United States | 1 | Completed | Nov 3, 2025 | 132 |
| NCT06308198Glabellar Lines · China, Japan, Taiwan | 3 | Completed | Feb 26, 2025 | 161 |
| NCT06151561Moderate to Severe Glabellar Lines · Japan | 1 | Completed | Apr 3, 2024 | 24 |
| NCT05496335Glabellar Lines · United States | 1 | Completed | May 30, 2023 | 90 |
| NCT05248893Glabellar Lines · United States, Puerto Rico | 3 | Completed | Jun 26, 2023 | 992 |
| NCT05248880Glabellar Lines · United States, Canada | 3 | Completed | Feb 1, 2023 | 309 |
| NCT05248867Glabellar Lines · United States, Canada, Germany and more | 3 | Completed | Mar 17, 2023 | 638 |
| NCT04096326Glabellar Lines · United States | 2 | Completed | Sep 9, 2020 | 198 |
How it is read
Names in the registry
- “AGN-151586”, 10 entries
- “TrenibotulinumtoxinE and OnabotulinumtoxinA”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.